Home

The Duke Human Vaccine Institute (DHVI) has established a place of national and international leadership in the fight against major infectious diseases. DHVI plays an integral leadership role in the Global HIV/AIDS Vaccine Enterprise and is a pioneer in emerging infections and biodefense research. By focusing on the scientific “bottlenecks” for the development of HIV, TB, and other vaccines, DHVI investigators continue to make significant contributions to overcome global health challenges on behalf of society. More

Press Releases

Human Immunodeficiency Virus

Recent Publications

IMPACT OF CLADE, GEOGRAPHY AND AGE OF THE EPIDEMIC ON HIV-1 NEUTRALIZATION BY ANTIBODIES.
Hraber P, Korber BT, Lapedes AS, Bailer RT, Seaman MS, Gao H, Greene KM, McCutchan F, Williamson C, Kim JH, Tovanabutra S, Hahn BH, Swanstrom R, Thomson MM, Gao F, Harris L, Giorgi E, Hengartner N, Bhattacharya T, Mascola JR, Montefiori DC. J Virol. 2014 Aug 20. pii: JVI.01705-14. [Epub ahead of print]

Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses.
Richard J, Veillette M, Batraville LA, Coutu M, Chapleau JP, Bonsignori M, Bernard N, Tremblay C, Roger M, Kaufmann DE, Finzi A. J Virol Methods. 2014 Aug 12. pii: S0166-0934(14)00310-3. doi: 10.1016/j.jviromet.2014.08.003. [Epub ahead of print]

HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria.
Trama AM, Moody MA, Alam SM, Jaeger FH, Lockwood B, Parks R, Lloyd KE, Stolarchuk C, Scearce R, Foulger A, Marshall DJ, Whitesides JF, Jeffries TL Jr, Wiehe K, Morris L, Lambson B, Soderberg K, Hwang KK, Tomaras GD, Vandergrift N, Jackson KJ, Roskin KM, Boyd SD, Kepler TB, Liao HX,Haynes BF. Cell Host Microbe. 2014 Aug 13;16(2):215-226. doi: 10.1016/j.chom.2014.07.003.

Video Presentations

Broadly neutralizing HIV-1 antibody identified in a lupus patient
March 11, 2014
Dr. Barton Haynes, DHVI and Duke CHAVI-ID Director, discusses recent findings from a study led by DHVI investigators in which a broadly neutralizing antibody was identified in a lupus patient who was chronically infected with HIV.